CCE project update

MetabolomicsRaftery Group

Original Study

-1

-0.5

0

0.5

1

1.5

0 5 10 15 20 25 30 35

Axis

Title

Axis Title

Cross-Validation on PLSDA model

Cancer

Healthy

20 cancer, 28 normals and 14 with polypsNMR and GC-MS study

CCE Samples and Experiments

Healthy Control

Colon Cancer Polyps Rectal

Cancer unknown

Sample number 46 14 32 4 14

Patient number 46 10* 32 2 14

*9 sample were collected before/on the day of treatment/surgery

110 Samples received (104 patients)

1H NMR experiment

• 26 metabolites quantified; 8 showed p<0.05 between cancer and normal•Unsupervised analysis on all samples showed little difference

• Supervised analysis in progress. Shows some separation but needs additional MS data

-0.6

-0.4

-0.2

0

0.2

0.4

0.6

0.8

-5 5 15 25 35 45 55Y C

V Pre

dicte

d 2 (C

lass 1

)

Sample number

PSLDA cross-validation

Healthy

Cancer

Boundary

more cancer samples needed for better discrimination model.

Multivariate analysis

• Seven metabolite model built on previous colon sample (17 Cancer, 17 Healthy), predict on CCE samples (14 Cancer, 46 Healthy, 32 Polyps)

-2

-1.5

-1

-0.5

0

0.5

1

1.5

2

0 20 40 60 80 100

Y Pr

edic

ted

2 (C

lass

1)

Sample number

PLSDA prediction on CCE

Healthy

Cancer

Polyps

Boundary

Q1: For those samples collected on the day of treatment, which were drawn before therapy or surgery?Q2: Are CCE samples collected as the same way as previous samples?

• Looks like colon cancer samples are failing, but many were collected after surgery.•Could be showing some treatment effect.